Response To: ‘Towards Optimal Cut-Off Trough Levels of Adalimumab and Etanercept for a Good Therapeutic Response in Rheumatoid Arthritis. Results of the INMUNOREMAR Study’ by Sanmartiet Al
Annals of the Rheumatic Diseases - United Kingdom
doi 10.1136/annrheumdis-2015-207543
Full Text
Open PDFAbstract
Available in full text
Date
April 3, 2015
Authors
Publisher
BMJ